Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

YS Biopharma Says PIKA Rabies Vaccine Effective after One-Week Dosing

publication date: Apr 12, 2024

Beijing’s YS Biopharma reported positive results from the ongoing Phase III clinical trial of its next-gen PIKA Rabies Vaccine. The company said interim results show that the vaccine has met its primary endpoints with potential to offer best-in-class accelerated protection and meet the WHO's goal of a one-week rabies vaccine regimen that would replace the usual three- or four-week regimens. YS Biopharma is a China-US biopharma that develops vaccines and therapeutic biologics for infectious diseases and cancer. More details....

Stock Symbol: (NSDQ: YS)

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital